Navigation Links
IROs Help Determine Medical Necessity of Growth Hormone Therapy
Date:4/14/2009

LANSDALE, Pa., April 14 /PRNewswire/ -- Today the human growth hormone (HGH) industry approaches $2 billion a year. It claims benefits for enhancing athletic performance, anti-aging and stimulating growth. Unfortunately, many of these remain unproven says NAIRO, trade association of independent review organizations (IROs) whose members see daily requests from health plans asking about the medical necessity of growth hormone therapies (www.nairo.org).

Because of its dangers, the Food and Drug Administration (FDA) tightly controls HGH and prohibits doctors from prescribing it for any use the agency has not specifically approved. For example, if doctors prescribe the drug to enhance athletic performance or reverse aging they are breaking the law.

"There's much confusion about growth hormone therapy, even among healthcare professionals," said Joyce Muller, NAIRO president. "Health plans wanting to determine the approved uses and standard of care for the drug should consult an IRO."

Limited Approval for Children

The FDA has approved HGH for children to treat rare genetic conditions, such as Prader-Willi Syndrome (PWS) or Pituitary Dwarfism where it has shown therapeutic benefits. In all cases, HGH treatment requires the assistance of a pediatric endocrinologist. Although it has some rare side effects, treatment with synthetic (recombinant) HGH is generally safe. FDA approved uses include idiopathic short stature, growth-hormone deficiency, and chronic kidney disease.

Anti-aging and Performance Enhancement Unproven

In 2002, the National Institute on Aging sponsored the most comprehensive single study on the anti-aging effects of HGH. It discovered marginal benefits and significant side effects. It warned that HGH should be limited "to controlled research studies" and not widely prescribed.

Despite professional sports outlawing HGH, the belief persists that it makes athletes stronger and faster. Nevertheless, there is insufficient scientific evidence to support this.

The FDA approves HGH in adults only for relatively rare diseases--adult growth hormone deficiency and the wasting syndrome of late stage AIDS. In these treatments, after diagnosing patients with extensive blood tests doctors must monitor them closely.

Unapproved used of HGH can lead to increased health problems including diabetes, heart problems, liver problems, kidney problems, cancer, or death. Moreover, purchasing HGH online is risky because of the possible lack of quality control by manufacturers not approved by the FDA that can result in contamination by other drugs or steroids. Additionally, HGH misuse and its related side effects can increase health plan administrative and litigation costs that cause consumer premiums to rise.

"Health plans should be cautious about approving HGH therapies," Muller said. "Because HGH carries sanctions for indications not approved by the FDA, health plans must consider the medical necessity of each case carefully to protect themselves, their providers, and their members. IROs can help them determine whether there's a real medical need."

For help finding an IRO to review the medical necessity of HGH therapy, health plans and payers can contact NAIRO (www.nairo.org).


'/>"/>
SOURCE NAIRO
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Discovery may result in new test to determine predisposition to cancer
2. Flax Council of Canada Announces GRAS Status Determined for Flax in U.S.
3. Right warfarin dose determined by 3 genes
4. New Jersey Plastic Surgeon Helps Determine Top Cosmetic Surgery Procedures of 2008
5. Lung cancer: Molecular scissors determine therapy effectiveness
6. Number of cardiovascular risk factors could determine safety of intravenous gammaglobulin treatment
7. Efficacy of stents is improved when their placement is determined by arterial blood flow measurement
8. One Mans Determined Journey to Remission and a Renewed Sense of Faith
9. CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine
10. CSHL scientists show how a protein that determines cell polarity prevents breast cancer
11. Penn scientists show how body determines optimal amount of germ-fighting B cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, ... with The Jensie Gran Fondo of Marin. For the second year in a ... broad-spectrum, mineral-based sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... Club in Miami Beach to host its Swirl: Miami Wine Tasting Event on ...
(Date:2/23/2017)... ... ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will be appearing ... which will begin airing on February 24, 2017. The show chronicles the weight loss ... television series, “Here Comes Honey Boo Boo.” The earlier series from TLC lasted for ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... approved content provider for the National Institute for Health and Care Excellence ... care-related organizations in the National Health Service (NHS) to search, order and purchase ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig ... where generations converge and explore the world from different perspectives. By providing a ... readers to gain understanding, increase empathy, and find greater happiness. , "Our ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... YORK , Feb. 23, 2017  This report ... Thousand by the following Products: Intermediates, ... in the report include Pharmaceuticals, and Agrochemicals. The report ... Japan , Europe , and ... for the period 2015 through 2022. Also, a six-year ...
(Date:2/24/2017)... YORK , Feb. 23, 2017  The ... 330.6 million by 2021 from USD 275.9 million ... Read the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... increasing spending on pharmaceutical R&D, and growth in ... driving the market growth for particle counters. On ...
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an ... that it has acquired exclusive worldwide rights to ... innovative HDAC inhibitor targeting hematological and solid tumors. ... Phase 1 and 2 clinical trials of Abexinostat ... have already been completed, demonstrating that Abexinostat ...
Breaking Medicine Technology: